Trial record 7 of 56 for:    " September 09, 2009":" October 09, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet (RMP02-MTN006)

This study has been completed.
Sponsor:
Collaborators:
Microbicide Trials Network
Information provided by:
CONRAD
ClinicalTrials.gov Identifier:
NCT00984971
First received: September 24, 2009
Last updated: November 1, 2010
Last verified: September 2010
  Purpose

To date, the majority of microbicide research has focused on the assessment of the safety and effectiveness of vaginal microbicides used for the prevention of HIV transmission via the vaginal compartment. Receptive anal intercourse (RAI) is common among men who have sex with men (MSM), and there is increasing evidence that heterosexual women in the developed and developing world also practice anal sex. It can, therefore, be anticipated that once vaginal microbicides are licensed, they will be used in both the vaginal and rectal compartments. As a consequence, there is a need to evaluate both the rectal and vaginal safety profile of candidate microbicides. Therefore, the primary objective of this study is to evaluate the systemic safety of 1% vaginally formulated tenofovir gel applied rectally. In addition, this study will evaluate the immunotoxicity of the gel and evaluate its acceptability; it will also use the oral tenofovir disoproxil fumarate tablets (TDF), rectally-applied tenofovir gel,and a placebo gel to compare their systemic and compartmental pharmacokinetic (pK) profiles.

This study was designed to address the following hypotheses:

  • Vaginally-formulated tenofovir 1% topical gel when applied rectally will be safe using a combination of clinical and laboratory markers including assays specifically designed to measure mucosal toxicity
  • Tenofovir will be detectable at different concentrations in the various anatomic compartments sampled for pharmacokinetics following single and 7-day topical exposures
  • Exposure to tenofovir 1% gel will demonstrate prevention of ex vivo HIV-1 challenge using in vivo drug-exposed tissue as compared to baseline tissue samples
  • Orally delivered, single dose, 300 mg tenofovir disoproxil fumarate tablets will have similar safety profiles using routine blood safety indices as have been established in other trials and will show no mucosal safety concerns
  • The oral dose will have different multi-compartment concentration kinetics than the topical tenofovir and will also demonstrate preliminary (ex vivo) prevention using the explant infectivity assay
  • Vaginally formulated tenofovir 1% topical gel applied rectally will be acceptable to participants, as indicated by a score in the upper one third of the 10-point Likert scale on intentionality to use in the product in the future

Condition Intervention Phase
HIV Prevention
HIV Infections
Drug: Tenofovir
Drug: HEC Placebo
Drug: Open label tenofovir tablet
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adults

Resource links provided by NLM:


Further study details as provided by CONRAD:

Primary Outcome Measures:
  • Grade 2 or higher clinical and laboratory adverse events as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0,Dec 2004 and Addenda 1 and 3 to this table. [ Time Frame: Every study visit ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Immunotoxicity, Pharmacokinetics, and Acceptability [ Time Frame: Immunotoxicity and pharmacokinetics: every study visit; acceptability: baseline and end of study ] [ Designated as safety issue: No ]

Enrollment: 18
Study Start Date: September 2009
Study Completion Date: July 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tenofovir Drug: Tenofovir
Topical gel applied rectally
Placebo Comparator: HEC Placebo Drug: HEC Placebo
Placebo gel applied rectally
Open label tenofovir tablet Drug: Open label tenofovir tablet
All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  1. ≥ Age of 18 at screening
  2. Willing and able to provide written informed consent for screening and enrollment
  3. HIV-1 uninfected at screening according to the standard DAIDS algorithm in Appendix II
  4. Willing and able to communicate in English
  5. Willing and able to provide adequate locator information, as defined in site standard operating procedures (SOP)
  6. Availability to return for all study visits, barring unforeseen circumstances
  7. Per participant report at screening, a history of consensual RAI at least once in the prior year
  8. Willing to abstain from insertion of anything rectally including sex toys, other than the study gel during the active phases of the study and for 5 days following biopsy collection
  9. Willing to abstain from sexual intercourse (rectal and vaginal) during the active phases of the study and for 5 days following biopsy collection
  10. Must agree to use study provided condoms for the duration of the study for vaginal and insertive anal intercourse
  11. Must be in general good health
  12. Must agree not to participate in other drug trials

    In addition to the criteria listed above, female participants must meet the following criteria:

  13. Post-menopausal or using (or willing to use) an acceptable form of contraception (e.g., barrier method, IUD, hormonal contraception, surgical sterilization, or vasectomization of male partner). If the female participant has female partners only, the method of contraception will be noted as a barrier method in the study documentation.

Exclusion Criteria

  1. Abnormalities of the colorectal mucosa, or significant colorectal symptom(s), which in the opinion of the clinician represents a contraindication to biopsy (including but not limited to presence of any unresolved injury, infectious or inflammatory condition of the local mucosa, and presence of symptomatic external hemorrhoids)
  2. At screening, clinical or laboratory diagnosis of active rectal or reproductive tract infection requiring treatment per current Centers for Disease Control and Prevention (CDC) guidelines or urinary tract infection (UTI). Infections requiring treatment include symptomatic bacterial vaginosis, symptomatic vaginal candidiasis, other vaginitis, trichomoniasis, Chlamydia (CT), gonorrhea (GC), syphilis, active HSV lesions, chancroid, pelvic inflammatory disease, genital sores or ulcers, cervicitis, or symptomatic genital warts requiring treatment. Note that HSV-2 seropositive with no active lesions is allowed, since treatment is not required.

    Note: Allow one re-screening after documented treatment (30 days) in cases of GC/CT identified at screening

  3. At screening:

    1. Positive for hepatitis B surface antigen
    2. Hemoglobin < 10.0 g/dL
    3. Platelet count < 100,000/mm3
    4. White blood cell count less than 2,000 cells/mm3 or > than 15,000 cells/mm3
    5. Calculated creatinine clearance less than 80 mL/min by the Cockcroft-Gault formula where creatinine clearance in mL/min (140- age in years) x (weight in kg) x (0.85 for females)/72 x (serum creatinine in mg/dL)
    6. Serum creatinine > 1.3× the site laboratory upper limit of normal (ULN)
    7. ALT and/or AST > 2.5× the site laboratory ULN
    8. +1 glucose or +1 protein on urinalysis (UA)
    9. History of bleeding problems (i.e. INR > 1.5× the site laboratory ULN or PTT > 1.25× the site laboratory ULN)
  4. History of significant gastrointestinal bleeding in the opinion of the investigator
  5. Allergy to methylparaben, propylparaben, sorbic acid
  6. By participant report at enrollment, history of excessive daily alcohol use (as defined by the CDC as heavy drinking consisting of an average consumption of more than 2 drinks per day for men, and more than 1 drink per day for women), frequent binge drinking or illicit drug use that includes any injection drugs, methamphetamines (crystal meth), heroin, or cocaine including crack cocaine, within the past 12 months
  7. Per participant report at screening, anticipated use and/or unwillingness to abstain from the following medications during the period of study participation:

    1. Heparin, including Lovenox®
    2. Warfarin
    3. Plavix® (clopidogrel bisulfate)]
    4. Rectally administered medications (including over-the-counter products)
    5. Aspirin
    6. NSAIDS
    7. Acyclovir
    8. Valacyclovir
    9. TDF
    10. Any other drugs that are associated with increased likelihood of bleeding following mucosal biopsy
  8. By participant report at screening, use of systemic immunomodulatory medications, rectally administered medications, rectally administered products (including condoms) containing N-9, or any investigational products within the 4 weeks prior to the Enrollment/Baseline Evaluation Visit
  9. History of recurrent urticaria
  10. Any other condition or prior therapy that, in the opinion of the investigator, would preclude informed consent, make study participation unsafe, make the individual unsuitable for the study or unable to comply with the study requirements. Such conditions may include, but are not limited to, current or recent history of severe, progressive, or uncontrolled substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, or cerebral disease.

    In addition to the criteria listed above, female participants will be excluded if they meet any of the following criteria:

  11. Pregnant at Enrollment/Baseline Evaluation Visit
  12. Breastfeeding or intent to breastfeed during duration of study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00984971

Locations
United States, California
UCLA Center for HIV Prevention Research
Los Angeles, California, United States, 90024
United States, Pennsylvania
University of Pittsburgh Clinical Research Unit
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
CONRAD
Microbicide Trials Network
  More Information

No publications provided by CONRAD

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Peter A. Anton, MD, UCLA
ClinicalTrials.gov Identifier: NCT00984971     History of Changes
Other Study ID Numbers: DAIDS ID 10769, RMP02-MTN006
Study First Received: September 24, 2009
Last Updated: November 1, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by CONRAD:
Microbicides
Tenofovir
HIV seronegativity

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Tenofovir
Tenofovir disoproxil
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-HIV Agents

ClinicalTrials.gov processed this record on August 18, 2014